首页 News 正文

Southern Finance and Economics, May 13 (Xinhua) - Zaiding Pharmaceutical Hong Kong Stock Exchange announced that the National Medical Products Administration of China has approved the use of reprotinib for the treatment of ROS1 positive non-small cell lung cancer patients.
您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

股海静观陶 新手上路
  • 粉丝

    0

  • 关注

    0

  • 主题

    0